AngioDynamics Inc. (NASDAQ:ANGO) issued its quarterly earnings results on Wednesday. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.04. AngioDynamics had a negative net margin of 12.57% and a positive return on equity of 3.94%. The business had revenue of $88.10 million for the quarter, compared to analysts’ expectations of $26.74 million.
Shares of AngioDynamics (NASDAQ:ANGO) opened at 17.30 on Wednesday. AngioDynamics has a 52 week low of $9.71 and a 52 week high of $17.64. The company has a 50-day moving average price of $16.76 and a 200-day moving average price of $14.25. The stock’s market cap is $630.10 million.
In related news, Director David F. Burgstahler sold 2,250,000 shares of the business’s stock in a transaction that occurred on Friday, August 5th. The stock was sold at an average price of $14.62, for a total value of $32,895,000.00. Following the transaction, the director now directly owns 23,988 shares of the company’s stock, valued at approximately $350,704.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Avista Capital Partners Gp, Ll sold 2,241,000 shares of the business’s stock in a transaction that occurred on Friday, August 5th. The stock was sold at an average price of $14.62, for a total value of $32,763,420.00. The disclosure for this sale can be found here. 1.88% of the stock is owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the company. Panagora Asset Management Inc. increased its stake in AngioDynamics by 53.5% in the second quarter. Panagora Asset Management Inc. now owns 31,077 shares of the company’s stock worth $447,000 after buying an additional 10,833 shares during the last quarter. Guggenheim Capital LLC increased its stake in AngioDynamics by 2.5% in the second quarter. Guggenheim Capital LLC now owns 78,480 shares of the company’s stock worth $1,128,000 after buying an additional 1,910 shares during the last quarter. Bridgeway Capital Management Inc. increased its stake in AngioDynamics by 111.5% in the second quarter. Bridgeway Capital Management Inc. now owns 66,400 shares of the company’s stock worth $954,000 after buying an additional 35,000 shares during the last quarter. C M Bidwell & Associates Ltd. purchased a new stake in AngioDynamics during the second quarter worth about $109,000. Finally, Parametric Portfolio Associates LLC increased its stake in AngioDynamics by 1.1% in the second quarter. Parametric Portfolio Associates LLC now owns 127,592 shares of the company’s stock worth $1,833,000 after buying an additional 1,436 shares during the last quarter. 69.29% of the stock is currently owned by institutional investors and hedge funds.
ANGO has been the subject of a number of analyst reports. KeyCorp set a $18.00 price objective on AngioDynamics and gave the company a “buy” rating in a research note on Monday, September 12th. Zacks Investment Research raised AngioDynamics from a “sell” rating to a “hold” rating in a research note on Monday, July 25th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $15.20.
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.